Aarti pharma labs has disclosed the creation of a pledge by promoter Mr. Renil Rajendra Gogri involving 15,19,919 shares of the company. The disclosure was made under Regulation 31(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, dated March 31, 2026.

Pledge Details and Financial Institutions

The pledge was created on March 25, 2026, in favor of three financial institutions. The encumbered shares represent 1.68% of the company's total share capital and have been pledged for personal use by the promoter.

Distribution Among Financial Institutions

The pledged shares have been distributed among three financial institutions in varying proportions. Aditya Birla Capital Limited received 3,19,919 shares (0.35% of share capital), while Bajaj Financial Securities Limited received 6,00,000 shares (0.66% of share capital). The remaining 6,00,000 shares were allocated to 360 One Distribution Services Limited.

Promoter Shareholding Context

As of December 31, 2025, the total promoter shareholding in Aarti Pharmalabs Limited stood at 3,90,66,368 shares, representing 43.10% of the total share capital. The current pledge represents 3.89% of the promoter's total shareholding in the company.

Regulatory Compliance

The encumbered shares constitute less than 50% of the promoter shareholding and less than 20% of the total share capital, ensuring compliance with regulatory thresholds. The disclosure confirms that all three entities in whose favor the shares have been pledged are recognized financial institutions, including scheduled commercial banks, public financial institutions, or NBFCs.

Key Highlights

• The pledge does not relate to any debt instruments such as debentures or commercial papers
• All regulatory disclosures have been made to both NSE and BSE
• The transaction is classified as a third-party pledge for personal use
• The digital signature on the disclosure was executed on April 2, 2026
• The company's shares are listed on both National Stock Exchange of India Limited and BSE Limited

Aarti pharma labs has received a single procedural Form 483 observation from the US Food and Drug Administration (FDA) following an inspection of its Tarapur Unit-IV manufacturing facility that concluded on March 27, 2026. The company has formally disclosed this development to stock exchanges under Regulation 30 of SEBI regulations and confirmed its commitment to address the regulatory requirement through timely submission of its Corrective and Preventive Action (CAPA) response.

FDA Inspection Outcome

The FDA inspection of the Tarapur Unit-IV facility, located at Plot No. E-50, 50/1, 59/1, MIDC, Tarapur, Tal. & District Palghar, Maharashtra, resulted in one procedural observation documented through Form 483. This regulatory document is issued by FDA inspectors when they identify conditions or practices that may constitute violations of FDA regulations during facility inspections.

Regulatory Disclosure and Company Response

Aarti Pharmalabs has formally notified BSE Limited and National Stock Exchange of India Limited about the inspection outcome through an official communication signed by Company Secretary and Legal Head Jeevan Mondkar. The company has indicated its intention to file the required CAPA documentation within the prescribed timeline, addressing the corrective and preventive actions for the observation along with compliance submission to the US FDA.

Regulatory Context

Form 483 observations are standard regulatory communications that pharmaceutical companies receive following FDA inspections. Companies typically have a stipulated period to respond to these observations with detailed plans for addressing the identified issues. The procedural nature of this observation suggests it relates to documentation or process compliance rather than product quality concerns, maintaining the facility's operational status while requiring administrative corrections.